FindTrial
Sign In

Effectiveness of Cilostazol in improving maturation rate of radiocephalic arteriovenous fistula in CKD stage 5: a randomized, double-blind, placebo-controlled trial

Effectiveness of Cilostazol in improving maturation rate of radiocephalic arteriovenous fistula in CKD stage 5

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190203002
Enrollment
132
Registered
2019-02-03
Start date
2018-11-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease patient whom need hemodialysis

Interventions

Cilostazol 200mg/day,Placebol 200 mg/day
Active Comparator Drug,Placebo Comparator Drug
Cilostazol,Placebo

Sponsors

Nakhon Pathom hospital
Lead Sponsor
Otsuka Pharmaceutical Factory Inc.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Radial artery and cephalic vein size at least 2 mm in diameter from ultrasound -Current hemodialysis patient -No infection at forearm area -To be informed and signed consent form

Exclusion criteria

Exclusion criteria: -History of allergic to Cilostazol -Current use of cilostazol -Heart failure of any severity

Design outcomes

Primary

MeasureTime frame
RCAVF maturation rate 3 months 1.RCAVF size at least 6 mm 2. Hemodialysis rate 300 ml/min 6 times within 30 days—

Secondary

MeasureTime frame
RCAVF Complication 3 months 1.thrombosis 2.infection 3.hemorrhage—

Contacts

Public ContactPrasopchai Kongsakphaisal

Nakhon Pathom hospital

Prasopchai099@gmail.com+66819361664

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026